[
    "{\"step_by_step_thinking\": \"ALVAC-HIV was tested in the HVTN 702 trial. To determine its effectiveness for HIV prevention, we need to refer to the relevant document. Document [3] provides information about the HVTN 702 trial. According to the document, the HVTN 702 trial evaluated the ALVAC-HIV plus bivalent subtype C gp120-MF59 vaccine regimen. However, the trial did not show efficacy in preventing HIV-1 infection among participants in South Africa. Therefore, the answer is B. no.\", \"answer_choice\": \"B\"}"
]